Table 3 Joint associations and interaction between hypertension polygenic risk scores (PRSs) and antihypertensive medication for liver-related outcomes among 25,726 subjects that were medication-naïve at baseline. Analyses are by Cox regression analyses.

From: Association between arterial hypertension and liver outcomes using polygenic risk scores: a population-based study

 

Overall (n = 25,726)

 

Excluding subjects with medication started > 5 years after baseline (n = 23,855)

HRa (95% CI)

P

HRa (95% CI)

P

Model with SBP PRS and medication

SBP PRS (per 1 SD)

1.28 (1.13–1.46)

 < 0.001

1.33 (1.14–1.55)

 < 0.001

Antihypertensive medication

0.93 (0.72–1.21)

0.598

0.76 (0.53–1.08)

0.127

Interaction term SBP PRS * antihypertensive medication

0.79 (0.63–0.98)

0.038

0.73 (0.53–1.02)

0.064

Model with DBP PRS and medication

DBP PRS (per 1 SD)

1.25 (1.10–1.42)

 < 0.001

1.37 (1.18–1.59)

 < 0.001

Antihypertensive medication

0.94 (0.72–1.21)

0.615

0.71 (0.49–1.03)

0.074

Interaction term DBP PRS * antihypertensive medication

0.81 (0.65–1.02)

0.072

0.93 (0.67–1.29)

0.661

  1. CI, confidence interval; HR, hazards ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PRS, polygenic risk score.
  2. aAdjusted for age, sex, body mass index, waist circumference, weekly alcohol use, fraction of alcohol use as wine, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, diabetes, exercise habits, smoking status (current, former, never smoker) and baseline cardiovascular disease, genotyping chip and the first three principal components of genetic structure.
Back to article page